Scontre Vanessa Armenio, Martins Janine Capobiango, de Melo Sette Claudia Vaz, Mutti Haila, Cubero Daniel, Fonseca Fernando, Del Giglio Auro
a Abc Foundation Medical School, Oncology , Faculdade de Medicina do ABC , Santo Andre , Brazil.
b Abc Foundation Medical School , Faculdade de Medicina do ABC , Santo Andre , Brazil.
J Diet Suppl. 2018 Sep 3;15(5):606-612. doi: 10.1080/19390211.2017.1366387. Epub 2017 Nov 2.
Hand-foot syndrome (HFS) is common and frequently occurs in the first cycle of treatment in approximately 40% to 50% of patients who receive capecitabine. Turmeric (Curcuma longa) is a plant used in Ayurvedic medicine with clinical activity in various inflammatory conditions. Our objective was to evaluate whether turmeric was active for the prevention of capecitabine-induced HFS. We included patients older than 18 years of age without previous exposure to capecitabine who were scheduled to receive this medication. Before starting treatment, after three weeks and at the end of six weeks, we evaluated dermatologic toxicity, conducted quality-of-life questionnaires (EORTC-QLQC30 and DLQI) and collected serum inflammatory biomarkers (inerleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), C-reactive protein (CRP), and albumin). We administered turmeric at a dose of 4 g/day (2 pills 12 hours apart) starting at the beginning of capecitabine treatment and lasting six weeks. We included 40 patients whose mean age was 62 years. Most were female (80%), 52% had breast cancer, and 47.5% had GI tumors. After the first cycle of capecitabine treatment, we observed that 11 of 40 patients developed HFS (27.5%; 95% CI [15, 42]), whereas four patients developed HFS equal or superior to grade 2 (10%; 95% CI [3.3, 23]). We did not find any correlations between the inflammatory markers tested and HFS. We show that turmeric combined with capecitabine seems to produce a lower rate of HFS, especially grade 2 or higher. These findings need to be reproduced in larger controlled studies.
手足综合征（HFS）很常见，在接受卡培他滨治疗的患者中，约40%至50%会在治疗的第一个周期频繁出现。姜黄（Curcuma longa）是一种用于阿育吠陀医学的植物，在各种炎症性疾病中具有临床活性。我们的目的是评估姜黄对预防卡培他滨诱导的HFS是否有效。我们纳入了18岁以上且之前未接触过卡培他滨、计划接受该药物治疗的患者。在开始治疗前、三周后和六周结束时，我们评估了皮肤毒性，进行了生活质量问卷调查（EORTC-QLQC30和DLQI），并收集了血清炎症生物标志物（白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、C反应蛋白（CRP）和白蛋白）。从卡培他滨治疗开始时起，我们以每天4克（每12小时2片）的剂量给予姜黄，持续六周。我们纳入了40名平均年龄为62岁的患者。大多数为女性（80%），52%患有乳腺癌，47.5%患有胃肠道肿瘤。在卡培他滨治疗的第一个周期后，我们观察到40名患者中有11名发生了HFS（27.5%；95%CI[15,42]），而有4名患者发生了2级或更高级别的HFS（10%；95%CI[3.3,23]）。我们未发现所检测的炎症标志物与HFS之间存在任何相关性。我们发现，姜黄与卡培他滨联合使用似乎能降低HFS的发生率，尤其是2级或更高级别的HFS。这些发现需要在更大规模的对照研究中得到验证。
